LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s.

Teva’s Emalex buyout falls under the company's wider strategy of prioritising deals around de-risked, differentiated, late-stage assets.

The JCA aims to centralise clinical assessment across the EU but tight timelines and stringent evidence requitements have cast doubt over the how fit for purpose the process is. Photo by Mahir Asadli ...

Regeneron raised GAAP gross margin on net product sales to 79% to 80% from 77% to 78%. Credit: viewimage / Shutterstock.com. Regeneron Pharmaceuticals has reported GAAP [Generally Accepted Accounting ...

Source is increasing in appeal across clinical research, offering sites and sponsors greater efficiencies in resources as budgets tighten, along with higher levels of precision and quality in data ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.

Arcera Life Sciences and Fosun Pharma have signed an MoU for a strategic long-term collaboration in the global life sciences industry.

Sun Pharma has signed a definitive agreement to acquire Organon in a transaction with an enterprise valuation of $11.75bn in cash.

A weak Q1 for Novartis that was heavily impacted by generics erosion showcases that the billions of dollars being spent by the pharma industry to shore up revenue streams amid a looming patent cliff ...